drugset
drugset / Trial / NCT07496463

Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)

NCT07496463 ↗

Phase 2 Not yet recruiting 1 enrolled Massachusetts General Hospital
NaSingle-groupOpen-labelTreatment

Summary

The investigators plan to test the efficacy and safey of 6-months of open-label setmelanotide to treat obesity in a single patient with pseudohypoparathyroidism type 1a due to a GNAS mutation.

Timeline

Start
2026-04-01
Primary completion
2026-10-01
Completion
2026-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Setmelanotide Protein / enzyme biologic 3 mg Subcutaneous

Indications

obesity disorder pseudohypoparathyroidism type 1A